Stock Financial Ratios

MYOV / Myovant Sciences Ltd. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)745.15
Enterprise Value ($M)606.70
Book Value ($M)166.78
Book Value / Share3.39
Price / Book6.49
NCAV ($M)166.94
NCAV / Share3.39
Price / NCAV6.27
Income Statement (mra) ($M)
Net Income-83.44
Balance Sheet (mrq) ($M)
Cash & Equivalents129.33
Cash / Share2.63
Quick Ratio10.04
Current Ratio10.04
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.50
Return on Assets (ROA)-0.45
Return on Equity (ROE)-0.50
Identifiers and Descriptors
Central Index Key (CIK)1679082
Industry Groups
Share Statistics
Common Shares Outstanding (M)60.99
Scoring Models
Piotroski F Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Inventory Work In Progress Per Share0.00
Assets Current Per Share2.71
Long Term Debt Per Share0.00
Liabilities Current Per Share0.31
Treasury Stock Per Share0.00
Equity Per Share2.41
Debt Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Liabilities Per Share0.32
Liabilities And Stock Equity Per Share2.77
Liabilities Other Non Current Per Share0.00
Intangibles Per Share0.00
Property Plant And Equipment Per Share0.02
Goodwill Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Retained Earnings Per Share-2.81
Assets Other Non Current Per Share0.04
Additional Paid In Capital Per Share5.22
Minority Interest Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Assets Per Share2.77
Accounts Receivable Per Share0.00
Inventory Raw Materials Per Share0.00
Assets Other Current Per Share0.00
Accounts Payable Per Share0.00
Inventory Finished Goods Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Inventory Per Share0.00
Property Plant And Equipment Net Per Share0.02
Cash And Equivalents Per Share2.63
Cash Per Share2.63

Related News Stories

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2017 Update

1h seekingalpha
Halvorsen's 13F portfolio value increased from $14.85B to $15.44B. The number of positions increased from 53 to 59. (1331-0)

BRIEF-Myovant Sciences secures flexible financing commitments

2017-10-16 reuters
* Myovant Sciences-‍under terms of agreement with Novaquest, co can request note purchases of up to $60 million at Myovant’s discretion through dec 31, 2018​ (14-0)

Myovant Sciences Announces Positive Top-line Results from Takeda's Phase 3 Study Evaluating the Efficacy and Safety of Relugolix Compared with Leuprorelin for the Treatment of Uterine Fibroids

2017-10-03 prnewswire
BASEL, Switzerland, Oct. 2, 2017 /PRNewswire/ -- Myovant Sciences (NYSE:  MYOV) today announced that Takeda Pharmaceutical Company Limited ("Takeda") has reported positive top-line results from a Phase 3 study evaluating the efficacy and safety of relugolix compared with leuprorelin for the treatment of uterine fibroids in Japanese women.  Relugolix was statistically non-inferior to leuprorelin (p = 0. (14-0)

Axovant Is An Excellent Short Opportunity After Failed Alzheimer's Results

2017-09-27 seekingalpha
Phase 3 data shows that no statistical significance was achieved in the intepirdine arm compared to placebo (235-1)

Myovant Sciences (MYOV) Presents at Baird's 2017 Global Healthcare Conference (Transcript)

2017-09-14 seekingalpha
Good afternoon, everyone. Welcome back from lunch. Thanks for coming today. I'm Brian Skorney, one of Baird’s Senior Biotech Analysts. The next company we have presenting is Myovant Sciences. Myovant is a relatively new IPOed company. With me, I have the CEO, Lynn Seely. Lynn thanks for joining us today. We really appreciate the time. (0-2)

CUSIP: G637AM102